Sequana Medical announces publication of results of alfapump® Multicentre, Post-Marketing Surveillance Registry in Alimentary Pharmacology & Therapeutics (AP&T).

Zurich, Switzerland: 4 October 2017 - Sequana Medical AG, a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of "Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis", the results of the first 56 patients in the alfapump® multicentre Post-Marketing Surveillance Registry (PMSR) in AP&T (Alimentary Pharmacology & Therapeutics).

In the largest reported series to-date of patients implanted with the alfapump®, the continuous drainage of ascites with the alfapump® led to a significant reduction in paracentesis frequency, with the median frequency of paracentesis dropped over 90%, from 2.17 to 0.17 per month.

More info on Sequana's website.


Next > PacBio and Bluebee launch de novo genome assembly pipeline on the Bluebee analysis platform

Previous > FRX Polymers secures AU$ 15.15 million in pre-IPO mezzanine exchangeable notes